World journal of urology · 2026
Clinical utility of urinary microRNA (miR-1273g-3p) in male patients with detrusor underactivity.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tachibana Masahiro, Aoyagi Chikao, Fujikawa Aiko, Yoshida Masaki, Sako Ryota, Yokoyama Riko, Yamashita Seiya, Miyahara Takuya, Noda Keisuke, Iwata Akito, Emoto Taiki, Tominaga Kosuke, Gunge Naotaka, Miyazaki Takeshi, Okabe Yu, Nakamura Nobuyuki, Haga Nobuhiro
Аннотация
PURPOSE: This study aimed to identify urinary microRNAs (miRNAs) as non-invasive biomarkers for pure detrusor underactivity (DU) without bladder outlet obstruction (BOO).
METHODS: Based on urodynamic study (UDS), patients were classified into non-BOO DU (n = 4), BOO (n = 4), young healthy control (n = 4), and older healthy control (n = 4) groups. Urinary miRNA profiles were analyzed by microarray to identify non-BOO DU-specific candidates. To validate the non-BOO DU-specific miRNA, RT-qPCR was performed in a validation cohort classified into non-BOO DU (n = 16) and BOO (n = 15, BOO or DU + BOO) groups. Diagnostic performance was assessed by receiver-operating characteristic (ROC) curve analysis, and cutoff values were determined. Clinical parameters were compared between groups stratified by the cutoff value.
RESULTS: Microarray analysis identified 28 urinary miRNAs with non-BOO DU-specific patterns in the exploratory cohort; hsa-miR-1273g-3p and hsa-miR-3940-5p were consistently downregulated in the non-BOO DU group in the validation cohort. ROC curve analysis showed an area under the curve (AUC) of 0.804 (95% CI 0.64-0.97) for 1273g-3p and 0.713 (95% CI 0.53-0.90) for 3940-5p. Using the cutoff value of 1273g-3p in the validation cohort, stratification showed no differences in age, BMI, post-void residual urine volume, or prostate volume, but significantly lower bladder outlet obstruction index (p = 0.033) and bladder contractility index (p = 0.021) in the low expression group.
CONCLUSIONS: Urinary miRNA profiling may represent a promising non-invasive diagnostic approach for non-BOO DU. In particular, hsa-miR-1273g-3p may be a potential biomarker for identifying patients with non-BOO DU.
METHODS: Based on urodynamic study (UDS), patients were classified into non-BOO DU (n = 4), BOO (n = 4), young healthy control (n = 4), and older healthy control (n = 4) groups. Urinary miRNA profiles were analyzed by microarray to identify non-BOO DU-specific candidates. To validate the non-BOO DU-specific miRNA, RT-qPCR was performed in a validation cohort classified into non-BOO DU (n = 16) and BOO (n = 15, BOO or DU + BOO) groups. Diagnostic performance was assessed by receiver-operating characteristic (ROC) curve analysis, and cutoff values were determined. Clinical parameters were compared between groups stratified by the cutoff value.
RESULTS: Microarray analysis identified 28 urinary miRNAs with non-BOO DU-specific patterns in the exploratory cohort; hsa-miR-1273g-3p and hsa-miR-3940-5p were consistently downregulated in the non-BOO DU group in the validation cohort. ROC curve analysis showed an area under the curve (AUC) of 0.804 (95% CI 0.64-0.97) for 1273g-3p and 0.713 (95% CI 0.53-0.90) for 3940-5p. Using the cutoff value of 1273g-3p in the validation cohort, stratification showed no differences in age, BMI, post-void residual urine volume, or prostate volume, but significantly lower bladder outlet obstruction index (p = 0.033) and bladder contractility index (p = 0.021) in the low expression group.
CONCLUSIONS: Urinary miRNA profiling may represent a promising non-invasive diagnostic approach for non-BOO DU. In particular, hsa-miR-1273g-3p may be a potential biomarker for identifying patients with non-BOO DU.